Surgery offers better OS for advanced SCLC

  • Zhang C & al.
  • Front Oncol
  • 01.01.2019

  • von Kelli Whitlock Burton
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Patients who underwent surgery for stage III small-cell lung cancer (SCLC) had significantly better OS vs those that did not receive surgery.

Why this matters

  • Although surgery is standard treatment in stage I SCLC, chemotherapy and radiotherapy are recommended for stage III disease.

Study design

  • 9606 patients diagnosed with stage III SCLC, 2004-2013, from the Surveillance, Epidemiology, and End Results database.
  • Propensity matching of 234 patient pairs.
  • Funding: Shandong First Medical University.

Key results

  • 2.4% underwent surgery.
  • The proportion of T1 stage patients and those with N0-N1 disease was higher in the surgical group than in the nonsurgical group (21.8% vs 11.1% and 26% vs 13.4%, respectively).
  • OS was significantly better in surgical patients before (P<.001 and after propensity matching.>
  • After multivariable analysis, surgery was significantly associated with better OS (HR, 0.651; P<.001>

Limitations

  • Retrospective study.